INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 447m ago
HOUSE PTR46m ago
SEC 13F46m ago
ROBINHOOD CHAIN46m ago
SEC FORM 4/Grant or awardVerified data

Zimmermann Martine reported LGND

Director · LIGAND PHARMACEUTICALS INC · LIGAND PHARMACEUTICALS INC — Non-Qualified Stock Option (right to buy)

Side
A
Value
—
Shares
2,938
Price
—
Executed
Jun 5, 2026
Disclosed
Jun 9, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 5 executedJun 9, 2026 disclosed

LGND · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LGND

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$140K
    440 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$39K
    120 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    2
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M$261K
    5,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$198K
    634 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$152K
    490 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$25K
    80 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$89K
    280 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$162K
    522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M—
    5,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$218K
    708 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$126K
    403 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$87K
    283 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$162K
    520 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$64K
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$102K
    320 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M—
    340 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    4
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$252K
    833 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$5,232
    17 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$72K
    235 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    8
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$600K
    1,976 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002001011-26-000101
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 5, 2026
    Published
    Jun 9, 2026
    Ingested by INSIDER
    Nov 5, 03:54 UTC
    Last re-read
    Nov 5, 03:54 UTC

    Extracted facts

    Filer
    Zimmermann Martine
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    LIGAND PHARMACEUTICALS INC — Non-Qualified Stock Option (right to buy)
    Ticker
    LGND
    Shares
    2,938
    Price per share
    $0
    Execution date (reported)
    Jun 5, 2026
    Owned after transaction
    2,938 shares
    Days from execution to publication
    4

    What this establishes

    Zimmermann Martine filed this Form 4 reporting a grant or award of LGND on Jun 5, 2026. It became public on Jun 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Zimmermann Martinecik:0001994049
    Issuer
    LIGAND PHARMACEUTICALS INCcik:0000886163

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.